Sysmex Corporation · TSE:6869

Sysmex — H1 FY2006 Earnings Presentation

22 slides from Sysmex's earnings presentation, November 2006

  1. Slide 1: Half Year 2006 Business Results

    Slide 1: Half Year 2006 Business Results

    A Unique & Global Healthcare Testing Company Half Year 2006 Business Results Financial Highlights and Future Opportunities Hisashi Ietsugu President and CEO SYSMEX CORPORATION

  2. Slide 2: Contents

    Slide 2: Contents

    Contents „Outline of Half Year 2006 Results „Results and Future Plans in Each Segment ¾ Geographical segments ¾ R&D segments „FY2006 Consolidated Earnings Forecast Forward-looking Statements This material contains forward-looking statements about Sysmex Corporation and its group companies (the Sysme

  3. Slide 3: Summary of Consolidated Statement FY2006 H.Y.

    Slide 3: Summary of Consolidated Statement FY2006 H.Y.

    Outline of Half Year 2006 Results Summary of Consolidated Statement FY2006 H.Y. (in billions of JPY) Exchange rate for FY2005 H.Y. : 50 10 US$1=¥109.5、EUR1=¥135.7 47.4 Exchange rate for FY 2006 H.Y. : 41.6 US$1= ¥115.4、EUR1=¥146.0 40 8 Profit&Loss Statement 36.2 „ Recorded „ Recorded excellent excel

  4. Slide 4: Breakdown of Net Sales and Ordinary Income

    Slide 4: Breakdown of Net Sales and Ordinary Income

    Outline of Half Year 2006 Results Breakdown of Net Sales and Ordinary Income ※FX impact excluded from regional sales below Gross margin increased as ・Increased SG&A Fix impact a result of a 0.3% ・R&D expenses: Up improvement in cost ratio ¥0.39 billion up1.9 ・Increased SG&A in (in billions of JPY) (

  5. Slide 5: Geographical Segment Information

    Slide 5: Geographical Segment Information

    Outline of Half Year 2006 Results Geographical Segment Information Japan <Including Korea and Taiwan> (in billions of JPY) (Net Sales to (Operating Income) Outside Customers) (Operating Eurpoe (Operating Icome) 35 30.3 6 Americas 27.9 Income) 15 (Net Sales to 3 30 25.5 10 1.5 11.8 (Net Sales to Outs

  6. Slide 6: Breakdown of Balance Sheet (Consolidated)

    Slide 6: Breakdown of Balance Sheet (Consolidated)

    Outline of Half Year 2006 Results Breakdown of Balance Sheet (Consolidated) Tangible fixed (in billions of JPY) Fixed assets assets Others 1.0 △0.2 Retained Up 0.83 Others earnings 0.82 Equity/Minority 0.37 interest Others 1.2 Current assets 3.1 Inventories 2.0 Up 4.0 △0.07 Liabilities Fixed Notes/A

  7. Slide 7: Consolidated Cash Flow

    Slide 7: Consolidated Cash Flow

    Outline of Half Year 2006 Results Consolidated Cash Flow 5 (In billions of JPY) 4.3 4.2 4.2 2.0 1.2 0.43 0.09 0 △0.57 △0.63 △1.6 △3.6 △ 3.5 △5 Net Increase in Operating CF Investing CF Finacing CF Cash and Cash Equivalents 2005.3 H.Y. 2006.3 H.Y. 2007.3 H.Y. ※Net Increase in Cash and Cash Equivalent

  8. Slide 8: New Products (to be) Released in FY2006

    Slide 8: New Products (to be) Released in FY2006

    Results and Future Plans in Each Segment New Products (to be) Released in FY2006 ‹ Hematology segment ‹ Urinalysis segment Automated hematology Urine cell analyzer analyzers UF-1000i XS Series Target area: Worldwide Target area: Worldwide Launch: Feb. 2006 in Japan, Launch: Jun. 2006 in Europe, and

  9. Slide 9: Americas: Sysmex's market recognition increasing

    Slide 9: Americas: Sysmex's market recognition increasing

    Results and Future Plans in Each Segment Americas Sysmex’s market recognition increasing! <Topics> ¾ Entered into an exclusive sales agreement with Midwest Health System, an affiliate of the US’s largest class hospital group HCA Automated hematology analyzers ¾ Experienced strong sales of the XT ser

  10. Slide 10: Strategic Priorities in the Commercial Lab Market

    Slide 10: Strategic Priorities in the Commercial Lab Market

    Results and Future Plans in Each Segment Topics Strategic Priorities in the Commercial Lab Market 【 Assumed customer concerns 】 ¾ Study of customers' analyzer selection process Evaluation point Concerns Increased productivity Not Concerns ¾ Strengthening communication and gaining trust Footprint sav

  11. Slide 11: Europe: Business steadily expanded by leveraging the Sysmex brand

    Slide 11: Europe: Business steadily expanded by leveraging the Sysmex brand

    Results and Future Plans in Each Segment Europe Business steadily expanded by leveraging the Sysmex brand <Topics> ¾ Saw strong sales of hematology analyzers through comprehensive proposal-oriented marketing ¾ Launched the system for rapid detection of breast cancer lymph node metastasis (April) ¾ E

  12. Slide 12: China: Influenced by the medical industry's clean-up campaign

    Slide 12: China: Influenced by the medical industry's clean-up campaign

    Results and Future Plans in Each Segment China Influenced by the medical industry’s “clean-up campaign” <Topics> ¾ Underwent cost suppression due to reduction of test expenses (insurance points) ¾ Experienced slow sales of instruments due to the medical industry’s “clean-up campaign” ¾ Earned strong

  13. Slide 13: Current Status and Future Prospect of Chinese Market

    Slide 13: Current Status and Future Prospect of Chinese Market

    Results and Future Plans in Each Segment Topics Current Status and Future Prospect of Chinese Market Background of the medical industry’s “clean-up campaign” and its impacts on Sysmex Qualitative change and <Negative impacts> expansion of targets z Hospitals refraining from purchasing in Chinese mar

  14. Slide 14: AP: Business opportunities in India accelerated

    Slide 14: AP: Business opportunities in India accelerated

    Results and Future Plans in Each Segment AP Business opportunities in India accelerated <Topics> ¾ Strengthen the marketing structure in India (Established Sysmex India) 9 Established a reagent factory in India ¾ Strong sales of the automated hematology analyzer XS series ¾ Promoted the solution bus

  15. Slide 15: Japan: Strengthened business worthy of a comprehensive supplier

    Slide 15: Japan: Strengthened business worthy of a comprehensive supplier

    Results and Future Plans in Each Segment Japan Strengthened business worthy of a comprehensive supplier <Topics> (in billions of JPY) (Net Sales to Outside (Operating ¾ Medical fee reimbursements decreased by 3.16% Japan Customers) Income) ¾ Received an increasing number of orders for large-scale 70

  16. Slide 16: Outline of Techno Park

    Slide 16: Outline of Techno Park

    Results and Future Plans in Each Segment Outline of Techno Park ¾¾Land Landarea: area:approx. approx.72 72thousand thousandsquare squaremeters, meters,twice twiceas aslarge largeas asthe thepresent presentR&D R&Dbase base ¾¾New Newbuilding buildingstructures: structures:R&D R&Dbuilding building(10(1

  17. Slide 17: Strategic Priorities in Strengthening R&D

    Slide 17: Strategic Priorities in Strengthening R&D

    Results and Future Plans in Each Segment Strategic Priorities in Strengthening R&D Risk Early Definitive Drug efficacy Prediction of diagnosis detection diagnosis prediction prognosis Source: Ministry of Economy, Trade and Industry Genetic analysis Genetic analysis Chip technology technology Necessa

  18. Slide 18: Progress in R&D

    Slide 18: Progress in R&D

    Results and Future Plans in Each Segment Progress in R&D Research Clinical trial Application/ Launch NHI price Approval listing (Clinical study) (Clinical trial) Launched in the European market in April „ Rapid detection technology for Colon Breast Japan: in preparation for lymph node metastasis can

  19. Slide 19: Current Status of Commercialization of Life Science

    Slide 19: Current Status of Commercialization of Life Science

    Results and Future Plans in Each Segment Current Status of Commercialization of Life Science Progress after the launch of the system for rapid detection Recognized as the highly of breast cancer lymph node metastasis added value testing Standardization of Market awareness activities methods to get (

  20. Slide 20: FY2006 Consolidated Earnings Forecast

    Slide 20: FY2006 Consolidated Earnings Forecast

    FY2006 Consolidated Earnings Forecast FY2006 Consolidated Earnings Forecast (Planned exchange rate: FY2006 Consolidated Earnings Forecast US$1= ¥115, EUR1= ¥145) ¾ Sales: ¥98 billion ¾ Operating income: ¥13.3 billion ¾ Net Income:¥ 8.2 billion ¾ Ratio of Ordinary income: 13.6% ¾ Ratio of Net Income

  21. Slide 21: Projected Dividend for FY2006

    Slide 21: Projected Dividend for FY2006

    FY2006 Consolidated Earnings Forecast Projected Dividend for FY2006 Interim Year-end Total dividend dividend FY2006 ¥16 ¥16 ¥32 ¥16 FY2005 ¥20 (including 2 yen ¥36 commemorative dividend) (Reference) Conversion to dividend ¥10 ¥16 ¥26 after share split (Note: Sysmex split its common shares on a 2 fo

  22. Slide 22: Challenging the Frontiers of Healthcare Testing

    Slide 22: Challenging the Frontiers of Healthcare Testing

    Challenging the Frontiers of Healthcare Testing SYSMEX CORPORATION <Contact> IR & Corporate Communication Div. Phone: 81-078-265-0500 Email: info@sysmex.co.jp URL: http://www.sysmex.co.jp A Unique & Global Healthcare Testing Company END

Source: Internet Archive copy of sysmex.co.jp

More decks from Sysmex Corporation

All 55 Sysmex decks